Seeking Alpha

User 6532771

User 6532771
Send Message
View as an RSS Feed
Latest  |  Highest rated
  • At $28K a vial, Questcor's (QCOR) Acthar has propelled shares to huge gains. QCOR bought the drug for $100K in 2001, planning to produce it only to treat infantile spasms. But thanks to aggressive marketing, it's now being prescribed for MS, arthritis, and kidney disease. Aetna's (AET) decision to limit off-label treatments has hit shares, but it's not clear any viable alternatives are on the horizon. (NYT[View news story]
    Recommended dose for MS relapse is 80 - 120 U daily for two weeks for an MS exacerbation. One vial is 5 mL at 80 U/mL, so around five days' worth. The cost is definitely in the tens of thousands which really is a tough sell for treating an MS relapse, since generally therapy during relapses has been found to offer symptomatic relief but to have no long term effects on disease progression (i.e. people feel better in the short term but they still have MS).
    Dec 30 04:40 PM | Likes Like |Link to Comment
COMMENTS STATS
1 Comment
0 Likes